Efficacy and safety of extended-release carbidopa-levodopa (IPX203) versus immediate-release carbidopa-levodopa for Parkinson's disease: A systematic review.

J Int Med ResSep 2, 2026 (epub)
Clinical ResearchNeurologyOpen access

Ahmed Attar, Hasen H Aljadani, Khalid F Barwais et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the efficacy and safety of extended-release carbidopa-levodopa (IPX203) versus immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease. The analysis included three randomized controlled trials with 560 participants. IPX203 significantly increased 'Good On-time' and reduced 'Off-time' compared to the immediate-release formulation.

Key findings

  • IPX203 increased total 'Good On-time' compared to immediate-release carbidopa-levodopa.
  • IPX203 reduced 'Off-time' in patients with advanced Parkinson's disease.
  • Motor function improvement was greater with IPX203 as per Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
  • Adverse events were comparable, but treatment-emergent adverse events were more frequent in the IPX203 group.

Why it matters

The findings suggest that IPX203 may offer improved symptom control and motor function in patients with advanced Parkinson's disease, potentially enhancing quality of life. Understanding these differences can inform treatment decisions.

Source

PubMed · PMID 42685769Free full text on PubMed Central

Published in J Int Med Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.